CG Oncology, Inc.

cgoncology.com

The filing excerpts provided do not contain sufficient business detail to construct a supported canonical description for CG Oncology Inc (NASDAQ: CGON). The excerpts consist only of SEC cover page boilerplate and do not disclose the company's core business activity, revenue model, products, customers, competitors, or financial data. A description cannot be written without fabricating facts not present in the source material.

Peers: Vericel Corp Celldex Therapeutics Inc Beam Therapeutics Inc Veracyte Inc IOVANCE BIOTHERAPEUTICS, INC. Intellia Therapeutics, Inc. Protagonist Therapeutics, Inc Apogee Therapeutics, Inc.

Source: SEC 10-K, filed 2026-02-27

Dive deeper

Financial Snapshot

Revenue

TTM

$6.228M

Gross Margin

TTM

-109.9%

Net Income

TTM

-$224.4M

Current Assets

2026 Q2

$1.050B

Current Liabilities

2026 Q2

$47.24M

Current Ratio

2026 Q2

2221.95%

Total Assets

2026 Q2

$1.086B

Total Liabilities

2026 Q2

$56.54M

Book Value

2026 Q2

1.029B

Cash

2026 Q2

$19.64M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$179.3M

Stock Price

Market Cap: $6.6188 Billion